Vitamin d status during winter months among children and adolescents with cystic fibrosis living in southern Russia

The article presents the results of vitamin D tests in children with cystic fibrosis and in healthy children living in the South of Russia. The study showed the high prevalence of vitamin D deficiency and inadequate levels in patients with cystic fibrosis (86.7%). 25(OH) D level characterizing the vitamin D status decreases progressively in patients and healthy children. With regard to the above mentioned, it is significantly lower in patients with cystic fibrosis than in healthy children in all age periods. The correlation between the serum calcidiol level and the age of patients with cystic fibrosis was r = -0.44 (p = 0.015). Intake of prophylactic (500--1000 IU/day) and therapeutic (1500--3000 IU/day) doses of cholecalciferol results in a less significant increase in calcidiol levels in patients with cystic fibrosis compared with healthy children. A significantly lower 25(OH)D level was detected in patients with cystic fibrosis infected with Staph. aureus. The 25(OH)D levels are significantly lower in children with cystic fibrosis and hypocholesterolemia, than in patients with normal cholesterol levels. Risk factors for the development of severe hypovitaminosis D in children with cystic fibrosis are age, physical developmental delay, exocrine pancreatic insufficiency, presence of chronic Staph. Aureus bronchopulmonary infection. Given the conducted study, the dosage of cholecalciferol in patients with cystic fibrosis should be at least 2 times higher than that in healthy children.

1. Mazurova N.V., Surkov A.N., Bushueva T.V. Adaptation to the disease and treatment of children with rare hereditary metabolic diseases and their parents. Aktualnye Problemy Psikhologicheskogo Znaniya. 2013;2:107–117. (In Russ).

2. Baidakova G.V., Zakharova E.Yu., Kanivets I.V., Konovalov F.A., Strelnikov V.V., Kutsev S.I. Diagnosis of congenital and hereditary diseases in children: achievements and development prospects. Vestnik Roszdravnadzora. 2016;3:27–33. (In Russ).

3. Kapranov N.I., Kashirskaya N.Yu. Cystic fibrosis. M.: ID «MEDPRAKTIKA-M», 2014, 672 p. (In Russ).

4. Shaginyan I.A., Chernukha M.Yu., Kapranov N.I., Kondratieva E.I., Kashirskaya N.Yu, et al. Consensus «Cystic fibrosis: definition, diagnostic criteria, therapy», Section «Microbiology and epidemiology of chronic respiratory infection in cystic fibrosis». Pediatr. 2016;8(1):80–96. (In Russ).

5. Krasovsky S.A., Samoilenko V.A., Amelina E.L. Cystic fibrosis: diagnosis, clinic picture, basic principles of therapy. AtmosferA. Pulmonologiya i Allergologiya. 2013;1:42-46. (In Russ).

6. Kondratieva E.I., Kashirskaya N.Yu., Roslavtseva E.A. Review of the national consensus «Cystic fibrosis: definition, diagnostic criteria, therapy» for nutritionists and gastroenterologists. Voprosy Detskoi Patologii. 2018;6(1):58–74. (In Russ).

7. Ivanova O.N. Cystic fibrosis in children. Uspekhi Sovremennoi Nauki. 2017;7:180–183. (In Russ).

8. Mogayzel P.J., Jr. and Flume P.A. Update in cystic fibrosis 2009. American Journal of Respiratory and Critical Care. 2010;181:539–544.

9. Polikarpova S.V., Kondratieva E.I., Shabalova L.A., Pivkina N.V., Zhilina S.V., Voronkova A.Yu., Sherman V.D., Nikonova V.S., Kapranov N.I., Kashirskaya N.Yu., Semykin S.Yu., Amelina E.L., Krasovsky S.A. The respiratory tract microflora in patients with cystic fibrosis and sensitivity to antibiotics. Meditsinsky Sovet. 2016;15:84–89. (In Russ).

10. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing cystic fibrosis. Strategies that increase life expectancy and improve quality of life. American Journal of Respiratory and Critical Care. 2011; 183:1463–1471.

11. Van de Weert-van Leeuwen P.B., Slieker M.G., Hulzebos H.J., Kruitwagen C.L.J.J., van der Ent C.K., Arets H.G.M. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. European Journal of Clinical Nutrition. 2011;39(4):893–898.

12. Gromova O.A., Torshin I.Yu., Martynov A.I. The role of vitamin D status in the regulation of immune function and antiinfective protection in adults. Terapiya. 2017;16(6):81–88. (In Russ).

13. Gromova O.A., Troshin I.Yu., Zakharova I.N., Malyavskaya S.I. The role of vitamin D in the regulation of immunity, prevention and treatment of infectious diseases in children. Meditsinsky Sovet. 2017;19:52– 60. (In Russ).

14. Averina I.A., Sergienko D.F., Duguzheva O.S., Gadzhiev R.M. Chronic lung diseases in the context of vitamin D immunogenetic effect. Uspekhi Sovremennoi Nauki. 2017;9(4):210-214. (In Russ).

15. Zakharova I.N., Kasyanov A.N., Klimov L.Ya., Kuryaninova V.A., Simakova M.A., Dedikova O.V., Koltsov K.A. Respiratory tract microbiome: what is known today? Pediatriya (Appendix. to the Consilium Medicum Journal.). 2018;4:10–17. (In Russ).

16. Kashirskaya N.Yu., Kapranov N.I. Digestive system dysfunction in patients with cystic fibrosis. Remedium. 2009;5:22–23. (In Russ).

17. Kashirskaya N.Yu., Sherman V.D., Kusova Z.A., Kapranov N.I. Digestive system in cystic fibrosis: management of the most important pathological conditions. Gastroenterologiya St. Petersburg. 2012;1:2–6. (In Russ).

18. Bartlett J.R., Friedman K.J., Ling S.C. et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302(10):1076–1083.

19. Gromova O.A., Troshin I.Yu. Vitamin D: paradigm shift. Under the editorship of Acad. of RAS E.I. Gusev, Prof. I.N. Zakharova. M.: TORUS PRESS, 2017. 576 p. (In Russ).

20. Tangpricha V., Kelly A., Stephenson A., Maguiness K., Enders J., Robinson K. A., Marshal B.C., Borowitz D. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. Journal Clinical Endocrinology and Metabolism. 2012;97(4):1082–1093.

21. Boyle M.P., Noschese M.L., Watts S.L., Davis M.E., Stenner S.E., Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2005;172(2):212–217.

22. Rovner A.J., Stallings V.A., Schall J.I., Leonard M.B., Zemel B.S. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. American Journal of Clinical Nutrition. 2007; 86(6):1694–1699.

23. Hall W.B., Sparks A.A., Aris R.M. Vitamin D deficiency in cystic fibrosis. International Journal of Endocrinology. 2010; Article ID 218691, 9 pages. doi:10.1155/2010/218691.

24. Finklea J.D., Grossmann R.E., Tangpricha V. Vitamin D and chronic lung disease: A review of molecular mechanisms and clinical studies. American Society for Nutrition. Adv. Nutr. 2011; 2:244–253.

25. Zosky G.R., Berry L.J., Elliot J.G., James A.L., Gorman Sh., Hart P.H. Vitamin D deficiency causes deficits in lung function and alters lung structure. American Journal of Respiratory and Critical Care. 2011; 183:1336–1343.

26. Li W., Dong H., Zhao H., Song J., Tang H., Yao L., Liu L., Tong W., Zou M., Zou F., Cai S. 1,25-dihydroxyvitamin D3 prevents toluene diisocyanate-induced airway epithelial barrier disruption. International Journal of Molecular Medicine. 2015; 36:263–270.

27. National program «Vitamin D deficiency in children and adolescents of the Russian Federation: modern approaches to treatment.» Union of Pediatricians of Russia [et al]. M.: Pediatr, 2018. 96 p. (In Russ).

28. Dolbnya S.V., Kuryaninova V.A., Abramskaya L.M., Aksenov A.G., Anisimov G.S., et al. Vitamin D and its biological role in humans. Communication 2. Non-calcemic effects of vitamin D. Vestnik Molodogo Uchenogo. 2015;4:24–34. (In Russ).

29. Zakharova I.N., Klimov L.Ya., Kasyanova A.N., Yagupova A.V., Kuryaninova V.A., Dolbnya S.V., et al. The role of antimicrobial peptides and vitamin D in the formation of anti-infective protection. Pediatriya. 2017;96(4):171–179. (In Russ).

30. Aleshina G.M., Kokryakov V.N., Shamova O.V., Orlov D.S, et al. Modern concept of antimicrobial peptides as molecular factors of immunity. Meditsinsky Akademichesky Zhurnal. 2010;4:149–160. (In Russ).

31. Pincikova T., Paquin-Proulx D., Sandberg JK., Flodström-Tullberg M., Hjelte L. Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. European Journal of Clinical Nutrition. 2017;71:203–205.

32. Kondratieva E.I., Zhekayte E.K., Shmargina G.V., Nikonova V.S., Voronkova A.Yu., Sherman V.D., Kostyuk S.V. Vitamin D levels at different periods of the year in patients with cystic fibrosis of the Moscow region. Voprosy Detskoi Dietologii. 2017;15(4):21–27. (In Russ).

33. Pashkevich, A.A., Borisenko, TS, Kaystrya, I.V., Orlov, A.V., Dorofeykov, V.V., Zhelenina, L.A., Kostik, M.M. Vitamin D deficiency in children with cystic fibrosis. Lechenie i Profilaktika. 2018;8:5–12. (In Russ).

34. Zakharova I.N., Klimov L.Ya., Maltsev S.V., Malyavskaya S.I., Kuryaninova V.A., Dolbnya S.V., et al. Vitamin D status and treatment of its deficiency in young children in the Russian Federation (a fragment of the National Program). Prakticheskaya Meditsina. 2017;5(106):22–28. (In Russ).

35. ЗахарZakharova, I.N., Tvorogova, TM, Solovieva, E.A., Sugyan, N.G., Antonenko, N.E., Balashova, N.D, et al. Vitamin D deficiency in children of Moscow, depending on the season of the year. Prakticheskaya Meditsina. 2017;5(106):28–31. (In Russ).

36. Zakharova I.N., Solovieva E.A., Klimov L.Ya., Vasilyeva S.V., Tvorogova T.M., Sugyan N.G., et al. The effectiveness of hypovitaminosis D treatment in older children living in Moscow. Meditsinsky Sovet. 2017;9:36–142. (In Russ)